HRP20211334T1 - Inzulin-fc fuzije i načini uporabe - Google Patents
Inzulin-fc fuzije i načini uporabe Download PDFInfo
- Publication number
- HRP20211334T1 HRP20211334T1 HRP20211334TT HRP20211334T HRP20211334T1 HR P20211334 T1 HRP20211334 T1 HR P20211334T1 HR P20211334T T HRP20211334T T HR P20211334TT HR P20211334 T HRP20211334 T HR P20211334T HR P20211334 T1 HRP20211334 T1 HR P20211334T1
- Authority
- HR
- Croatia
- Prior art keywords
- insulin
- fusion protein
- sek
- seq
- diabetes
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 claims 8
- 102000037865 fusion proteins Human genes 0.000 claims 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000003345 hyperglycaemic effect Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (10)
1. Inzulin-Fc fuzijski protein koji sadrži inzulinski polipeptid kondenziran na Fc domenu, naznačen time, što inzulinski polipeptid sadrži peptid B lanca, peptid C lanca i peptid A lanca, u kojem aminokiselinska sekvenca inzulin-Fc fuzijskog proteina je SEK ID BR: 2, SEK ID BR: 3, SEK ID BR: 4, SEK ID BR: 5, SEK ID BR: 6, SEK ID BR: 7, ili SEK ID BR: 8.
2. Rekombinantna sekvenca nukleinske kiseline koja kodira fuzijski protein inzulin-Fc je izabrana iz grupe koja se sastoji od SEK ID BR: 2, SEK ID BR: 3, SEK ID BR: 4, SEK ID BR: 5, SEK ID BR: 6, SEK ID BR: 7, i SEK ID BR: 8.
3. Vektor koji sadrži rekombinantnu sekvencu nukleinske kiseline sukladno patentnom zahtjevu 2.
4. Konstruirana eukariotska stanica koja sadrži spomenuti vektor sukladno patentnom zahtjevu 3.
5. Komplet koji sadrži inzulin-Fc fuzijski protein sukladno patentnom zahtjevu 1, uputstva za uporabu, bočice otapala, šprice i igle.
6. Komplet sukladno patentnom zahtjevu 5, nadalje sadrži sredstvo za puferiranje, konzervans, sredstvo za stabiliziranje.
7. Inzulin-Fc fuzijski protein sukladno patentnom zahtjevu 1, za uporabu u liječenju ili prevenciji autoimunog dijabetesa kod subjekta kojem je to potrebno.
8. Inzulin-Fc fuzijski protein za uporabu sukladno patentnom zahtjevu 7, naznačen time, da autoimuni dijabetes obuhvaća dijabetes tipa 1, maloljetnički dijabetes, inzulin-ovisni dijabetes ili latentni autoimuni dijabetes.
9. Inzulin-Fc fuzijski protein za uporabu sukladno patentnom zahtjevu 7 ili 8, gdje je subjekt dijagnosticiran s ili postoji rizik od autoimunog dijabetesa.
10. Inzulin-Fc fuzijski protein za uporabu sukladno patentnim zahtjevima 7-9, naznačen time, što subjekt nije hiperglikemičan.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432268P | 2016-12-09 | 2016-12-09 | |
| US201762514460P | 2017-06-02 | 2017-06-02 | |
| US201762514449P | 2017-06-02 | 2017-06-02 | |
| US201762514427P | 2017-06-02 | 2017-06-02 | |
| EP17878116.7A EP3551209B1 (en) | 2016-12-09 | 2017-12-08 | Insulin-fc fusions and methods of use |
| PCT/US2017/065456 WO2018107117A1 (en) | 2016-12-09 | 2017-12-08 | Insulin-fc fusions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211334T1 true HRP20211334T1 (hr) | 2021-11-26 |
Family
ID=62491387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211334TT HRP20211334T1 (hr) | 2016-12-09 | 2021-08-19 | Inzulin-fc fuzije i načini uporabe |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11359001B2 (hr) |
| EP (2) | EP3939605A1 (hr) |
| JP (2) | JP7170332B2 (hr) |
| CN (1) | CN110612112B (hr) |
| AU (2) | AU2017371217B2 (hr) |
| BR (1) | BR112019011860A2 (hr) |
| CA (1) | CA3046337C (hr) |
| DK (1) | DK3551209T3 (hr) |
| HR (1) | HRP20211334T1 (hr) |
| HU (1) | HUE055417T2 (hr) |
| LT (1) | LT3551209T (hr) |
| SI (1) | SI3551209T1 (hr) |
| WO (1) | WO2018107117A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3046337C (en) | 2016-12-09 | 2021-06-01 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| EP3655006B1 (en) | 2018-06-29 | 2021-11-17 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| WO2021011827A1 (en) * | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| US11352407B2 (en) * | 2019-12-19 | 2022-06-07 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| FI3972987T3 (fi) * | 2020-04-10 | 2023-07-25 | Akston Biosciences Corp | Antigeenispesifinen immunoterapia COVID-19-fuusioproteiineille ja sen käyttömenetelmät |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US20230272030A1 (en) * | 2020-07-24 | 2023-08-31 | Jiangsu Gensciences Inc. | Insulin-fc fusion protein and application thereof |
| WO2023004406A2 (en) * | 2021-07-23 | 2023-01-26 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JPH07116160B2 (ja) | 1987-08-10 | 1995-12-13 | 浜理薬品工業株式会社 | 結晶性ｌ−カルノシン亜鉛錯体およびその製造法 |
| EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| CN1125081C (zh) * | 1999-09-08 | 2003-10-22 | 中国科学院上海生物化学研究所 | 重组天然和新型人胰岛素及其制备方法 |
| US20030040601A1 (en) * | 2001-06-08 | 2003-02-27 | Ivan Diers | Method for making insulin precursors and insulin analog precursors |
| US8569231B2 (en) | 2009-03-20 | 2013-10-29 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| CA2754408A1 (en) | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Fusion proteins comprising canine fc portions |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
| CA2805739A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| AU2011282988A1 (en) * | 2010-07-28 | 2013-01-31 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| JP5890516B2 (ja) * | 2011-06-17 | 2016-03-22 | ハロザイム インコーポレイテッド | ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法 |
| AR087433A1 (es) | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| CA2854806A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| US20140302028A1 (en) | 2011-11-18 | 2014-10-09 | Merck Sharp & Dohme Corp. | Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding |
| KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| CN103509118B (zh) | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
| PT2963056T (pt) | 2013-02-26 | 2020-02-19 | Hanmi Pharm Ind Co Ltd | Análogo de insulina e utilização do mesmo |
| EP3194429A4 (en) | 2014-09-18 | 2018-06-13 | Askgene Pharma, Inc. | Novel feline erythropoietin receptor agonists |
| WO2016105545A2 (en) | 2014-12-24 | 2016-06-30 | Case Western Reserve University | Insulin analogues with enhanced stabilized and reduced mitogenicity |
| EP3250589A4 (en) | 2015-01-29 | 2018-06-20 | Nexvet Australia Pty Ltd | Therapeutic and diagnostic agents |
| CN107810202A (zh) | 2015-02-17 | 2018-03-16 | 韩美药品株式会社 | 长效胰岛素或胰岛素类似物复合物 |
| BR112017023646A2 (pt) | 2015-05-04 | 2018-07-17 | Apogenix Ag | proteínas agonistas de receptor de cd40 de cadeia simples |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| JP6983075B2 (ja) | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー／エス | 極性の組換え延長部を有するインスリン |
| EP3960760A1 (en) | 2015-11-16 | 2022-03-02 | Ubiprotein, Corp. | A method for extending half-life of a protein |
| US20180009869A1 (en) | 2016-07-08 | 2018-01-11 | AskGene Pharma, Inc. | Fusion Protein Comprising Leptin and Methods for Producing and Using the Same |
| BR112019005637A2 (pt) | 2016-09-23 | 2019-07-30 | Hanmi Pharm Ind Co Ltd | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso |
| US20200181258A1 (en) | 2016-10-17 | 2020-06-11 | Vetoquinol Sa | Modified antibody constant region |
| CA3046337C (en) | 2016-12-09 | 2021-06-01 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| AR111122A1 (es) | 2017-03-07 | 2019-06-05 | Univ Case Western Reserve | Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro |
| MX2020001707A (es) | 2017-08-15 | 2020-03-20 | Kindred Biosciences Inc | Variantes igg fc para uso veterinario. |
| KR20210005630A (ko) | 2018-04-16 | 2021-01-14 | 유니버시티 오브 유타 리서치 파운데이션 | 글루코스-반응성 인슐린 |
| EP3655006B1 (en) | 2018-06-29 | 2021-11-17 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| EP3856760A1 (en) | 2018-09-25 | 2021-08-04 | AbSci, LLC | Protein purification methods |
| TW202028229A (zh) | 2018-10-05 | 2020-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 包含胰島素肽及ｅｇｆ（ａ）肽之雙功能化合物 |
| CN113330025A (zh) | 2018-11-19 | 2021-08-31 | 卡斯西部储备大学 | 具有聚丙氨酸c结构域子区段的单链胰岛素类似物 |
| EP3969467A4 (en) | 2019-05-17 | 2023-07-05 | Case Western Reserve University | VARIANT SINGLE STREAM INSULIN ANALOGS |
| WO2021011827A1 (en) | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| TW202120536A (zh) | 2019-07-31 | 2021-06-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
-
2017
- 2017-12-08 CA CA3046337A patent/CA3046337C/en active Active
- 2017-12-08 SI SI201730909T patent/SI3551209T1/sl unknown
- 2017-12-08 HU HUE17878116A patent/HUE055417T2/hu unknown
- 2017-12-08 EP EP21181286.2A patent/EP3939605A1/en active Pending
- 2017-12-08 DK DK17878116.7T patent/DK3551209T3/da active
- 2017-12-08 LT LTEPPCT/US2017/065456T patent/LT3551209T/lt unknown
- 2017-12-08 AU AU2017371217A patent/AU2017371217B2/en active Active
- 2017-12-08 US US16/468,182 patent/US11359001B2/en active Active
- 2017-12-08 BR BR112019011860A patent/BR112019011860A2/pt unknown
- 2017-12-08 EP EP17878116.7A patent/EP3551209B1/en active Active
- 2017-12-08 JP JP2019551507A patent/JP7170332B2/ja active Active
- 2017-12-08 WO PCT/US2017/065456 patent/WO2018107117A1/en unknown
- 2017-12-08 CN CN201780085106.8A patent/CN110612112B/zh active Active
-
2019
- 2019-06-12 US US16/438,681 patent/US10597435B2/en active Active
-
2020
- 2020-08-31 AU AU2020227002A patent/AU2020227002B2/en active Active
-
2021
- 2021-08-19 HR HRP20211334TT patent/HRP20211334T1/hr unknown
-
2022
- 2022-10-25 JP JP2022170351A patent/JP2023017806A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023017806A (ja) | 2023-02-07 |
| AU2017371217B2 (en) | 2020-03-19 |
| WO2018107117A1 (en) | 2018-06-14 |
| US11359001B2 (en) | 2022-06-14 |
| BR112019011860A2 (pt) | 2019-11-12 |
| AU2020227002A1 (en) | 2020-09-17 |
| EP3939605A1 (en) | 2022-01-19 |
| AU2017371217A1 (en) | 2019-07-25 |
| HUE055417T2 (hu) | 2021-11-29 |
| JP7170332B2 (ja) | 2022-11-14 |
| JP2020503889A (ja) | 2020-02-06 |
| US20190315828A1 (en) | 2019-10-17 |
| SI3551209T1 (sl) | 2021-10-29 |
| CA3046337C (en) | 2021-06-01 |
| US10597435B2 (en) | 2020-03-24 |
| US20200131243A1 (en) | 2020-04-30 |
| EP3551209A1 (en) | 2019-10-16 |
| EP3551209A4 (en) | 2020-06-03 |
| EP3551209B1 (en) | 2021-06-30 |
| LT3551209T (lt) | 2021-09-10 |
| CA3046337A1 (en) | 2018-06-14 |
| CN110612112B (zh) | 2024-03-29 |
| DK3551209T3 (da) | 2021-08-23 |
| AU2020227002B2 (en) | 2024-02-01 |
| CN110612112A (zh) | 2019-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211334T1 (hr) | Inzulin-fc fuzije i načini uporabe | |
| CL2019001000A1 (es) | Proteínas de fusión fc heterodiméricas il15/il15ralfa | |
| UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
| ECSP17073650A (es) | Proteínas de fusión | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| EA201790063A1 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
| MY191030A (en) | Gdf15 fusion proteins and uses thereof | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| MX2019007367A (es) | Ligandos de peptido para enlace a mt1-mmp. | |
| PE20190743A1 (es) | Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib | |
| WO2016195982A3 (en) | Hepatitis b virus capsid assembly | |
| RU2011106744A (ru) | Инсулин, стабилизированный галогеном | |
| HRP20221531T1 (hr) | Pripravci faktora viii i postupci dobivanja i korištenja istih | |
| JP2017536337A5 (hr) | ||
| MX2020010466A (es) | Vectores de virus que evitan anticuerpos. | |
| PH12019500485A1 (en) | Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use | |
| MX2021000047A (es) | Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma. | |
| MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| RU2016145061A (ru) | Профилактическая вакцина против синдрома падения яйценоскости (eds) | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| MX2020010464A (es) | Vectores de virus que evitan anticuerpos. | |
| RU2017114673A (ru) | Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение | |
| JP2015524403A5 (hr) |